Clinical Trials

44 enrolled

Locally Advanced Rectal Cancer

NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

44 enrolled

Phase 1 Active not recruiting

Rectal Cancer Patients

NCT06654297 2026-04-02

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

6 enrolled

Esophageal Squamous Cell Carcinoma

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07320586 2026-03-13

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

40 enrolled

Phase 2 Active not recruiting

Stomach Neoplasms

NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

30 enrolled

Advanced Biliary Tract Carcinoma

NCT07395063 2026-02-09

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

68 enrolled

Colorectal Neoplasms

NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

157 enrolled 17 charts

Phase 3 Active not recruiting

Advanced Primary Liver Cancer

NCT05198609 2026-01-21

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

214 enrolled

Carcinoma, Hepatocellular

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Phase 3 Recruiting

550 enrolled

Stomach Neoplasms

NCT07314372 2026-01-20

FAD-HCC-001

86 enrolled

Carcinoma, Hepatocellular

NCT07324473 2026-01-07

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

65 enrolled

Phase 2 Enrolling by invitation

Carcinoma, Hepatocellular

NCT07312578 2025-12-31

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

48 enrolled

Phase 3 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

687 enrolled

Carcinoma, Hepatocellular

NCT06361888 2025-12-30

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Phase 2/3 Recruiting

502 enrolled

Phase 2/3 Not yet recruiting

Pancreatic Neoplasms

NCT07309419 2025-12-30

Cocktail-001

222 enrolled

Carcinoma, Hepatocellular

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT05176002 2025-11-19

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

25 enrolled

Esophageal Neoplasms

NCT06869226 2025-10-02

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

283 enrolled

Esophageal Neoplasms

NCT07191977 2025-09-25

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

41 enrolled

Esophageal Squamour Cell Cancer

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

885 enrolled

Stomach Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT06215677 2025-09-05

NITDC

Phase NA Recruiting

18 enrolled

Turcot syndrome, Colonic Neoplasms

NCT07100392 2025-08-17

LEAF-02

141 enrolled

Carcinoma, Hepatocellular

NCT07105748 2025-08-17

TASK-05

45 enrolled

Liver Neoplasms

NCT07057089 2025-08-14

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

90 enrolled

Locally Advanced Rectal Cancer

NCT06196671 2025-08-07

PTCA199-8

30 enrolled

Phase NA Not yet recruiting

Pancreatic Neoplasms

NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

98 enrolled

Esophageal Squamous Cell Carcinoma

NCT04625803 2025-06-17

Neoadjuvant Therapy for Locally Advanced Colon Cancer

64 enrolled 11 charts

Phase 2/3 Active not recruiting

Colonic Neoplasms

NCT04521153 2025-05-11

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

294 enrolled

Carcinoma, Hepatocellular

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

106 enrolled

Phase 2 Enrolling by invitation

Advanced Gastric Cancer

NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

50 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma

NCT04510064 2025-03-12

Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial

40 enrolled

Stomach Neoplasms

NCT04299581 2025-02-27

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

25 enrolled

Cholangiocarcinoma

NCT05236699 2025-02-14

CCGLC-005

23 enrolled

Cholangiocarcinoma

NCT06759090 2025-01-06

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

43 enrolled

Pancreatic Neoplasms

NCT05218889 2024-12-31

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

90 enrolled

Pancreatic Neoplasms

NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

35 enrolled

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

NCT05613478 2024-12-31

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Phase 3 Recruiting

130 enrolled

Carcinoma, Hepatocellular

NCT03878472 2024-12-16

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

25 enrolled

Stomach Neoplasms

NCT06711471 2024-12-02

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

31 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT05003700 2024-11-05

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

39 enrolled

Carcinoma, Hepatocellular

NCT04294784 2024-11-04

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Phase 2 Terminated

58 enrolled

Stomach Neoplasms

NCT06632522 2024-10-09

Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .

46 enrolled

Liver Neoplasms

NCT06061276 2024-09-23

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Phase NA Recruiting

40 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular, Liver Diseases

NCT04515615 2024-09-19

Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

52 enrolled

Stomach Neoplasms

NCT06546280 2024-08-09

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

38 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular

NCT04483284 2024-08-01

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

28 enrolled

Carcinoma, Hepatocellular

NCT05412589 2024-07-31

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

35 enrolled